About Drug Discovery and Clinic
DDC aims the pharmaceutical development of Dihydroorotate Dehydrogenase inhibitors and has the goal of bringing its best molecule to the clinical stage within 1 or 2 years. It is a potential new drug for the treatment of Acute Myeloid Leukemia (AML) that could significantly improve patient’s survival over 5 years.
What we do
DRUG DESIGN & HIT TO LEAD PROCESS
DRUG DESIGN & HIT TO LEAD PROCESS
DRUG DESIGN & HIT TO LEAD PROCESS
ACUTE MYELOID LEUKEMIA (AML)
DRUG DESIGN & HIT TO LEAD PROCESS
DRUG DESIGN & HIT TO LEAD PROCESS
